BioTuesdays

Tag - H.C. Wainwright

electroCore Logo
Markets

HCW ups electroCore PT to $2.50 from $1.50

H.C. Wainwright raised its price target for electroCore (NASDAQ:ECOR) to $2.50 from $1.50, citing the FDA’s emergency use authorization of gammaCore, the company’s lead product, to treat COVID-19 patients. The stock...

July 15, 2020
Aimmune Therapeutics
Markets

HCW halves Aimmune Therapeutics PT to $15 from $30

H.C. Wainwright halved its price target for Aimmune Therapeutics (NASDAQ:AIMT) to $30 from $15, and reiterated its “neutral” rating, citing the pandemic’s impact on the launch of Palforzia, the first drug treatment of...

May 12, 2020
Pulse Biosciences Logo
Markets

HCW ups Pulse Biosciences PT to $16 from $6

H.C. Wainwright raised its price target for Pulse Biosciences (NASDAQ:PLSE) to $16 from $6, citing the company’s agreement with the FDA on requirements for a 510(k) submission for a general dermatological indication of...

May 12, 2020
Precigen Logo
Markets

HCW starts Precigen at buy; PT $5

H.C. Wainwright initiated coverage of Precigen (NASDAQ:PGEN) with a “buy” rating and $5 price target. The stock closed at $3.17 on May 7. Precigen, previously known as Intrexon, is focused on applying synthetic biology...

May 8, 2020
PolarityTE Logo
Markets

HCW cuts PolarityTE to neutral and removes PT

H.C. Wainwright downgraded PolarityTE (NASDAQ:PTE) to “neutral” from “buy” and removed its price target, citing the clinical and regulatory risk from a strategy shift for its wound closure product, SkinTE. The stock...

May 4, 2020
Keros Therapeutics Logo
Markets

Analysts start Keros Therapeutics at buy, OP

Analysts for H.C. Wainwright and SVB Leerink launched coverage of Keros Therapeutics (NASDAQ:KROS) with “buy” and “outperform” ratings, respectively, citing Keros’ pipeline and platform differentiation. HCW analyst...

May 4, 2020
Xenetic Biosciences Logo
Markets

HCW starts Xenetic Biosciences at buy; PT $2

H.C. Wainwright initiated coverage of Xenetic Biosciences (NASDAQ:XBIO) with a “buy” rating and price target of $2. The stock closed at 86 cents on May 1. The main focus of the company is development of XCART, a CAR-T...

May 4, 2020
Bicycle Therapeutics Logo
Markets

HCW starts Bicycle Therapeutics at buy; PT $25

H.C. Wainwright initiated coverage of Bicycle Therapeutics (NASDAQ:BCYC) with a “buy” rating and $25 price target. The stock finished at $14.66 on April 17. The company is focused on bicycles, which are synthetic, short...

April 20, 2020